Form 8-K bluebird bio, Inc. For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer Says
November 5, 2015 11:00 AM ESTOppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.
Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More
bluebird bio (BLUE) Posts Wider-than-Expected Q3 Loss
November 5, 2015 6:45 AM ESTbluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($1.18), $0.24 worse than the analyst estimate of ($0.94). Revenue for the quarter came in at $1.32 million versus the consensus estimate of $5.2 million.
Cash, cash equivalents and marketable securities as of September 30, 2015 were $901.7 million, compared to $492.0 million as of... More
